Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia.
COVID-19
Oxford–AstraZeneca COVID-19 vaccine
Pfizer COVID-19 vaccine
Saudi Arabia
demographics
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
18 Feb 2022
18 Feb 2022
Historique:
received:
19
01
2022
revised:
11
02
2022
accepted:
13
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
Saudi Arabia expedited the approval of some COVID-19 vaccines and launched mass vaccination campaigns. The aim of this study was to describe the demographics of vaccinated COVID-19 cases and compare the mortality rates of COVID-19 cases who were infected post-vaccination in Saudi Arabia. This was a retrospective cohort study. We retrieved data for COVID-19 cases who were infected pre- or post-vaccination and had received at least one injection of the Oxford-AstraZeneca or Pfizer-BioNTech vaccine from 4 December 2020 to 15 October 2021. The number of patients who were infected and had received at least one dose of a COVID-19 vaccine was 281,744. Approximately 45% of subjects were infected post-vaccination, and 75% of subjects had received the Pfizer-BioNTech vaccine. Only 0.342% of the patients who were infected post-vaccination died, and 447 patients were admitted to ICUs. Most of the patients who were infected with COVID-19 post-vaccination and were admitted to ICUs (69.84%) had received only one dose of the vaccine ( Vaccines are vital in combating the COVID-19 pandemic. The results of this study show no difference between the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in the rate of mortality. However, the number of vaccine doses was significantly associated with a lower risk of mortality. Future studies should examine the effectiveness of different COVID-19 vaccines using real-world data and more robust designs.
Sections du résumé
BACKGROUND
BACKGROUND
Saudi Arabia expedited the approval of some COVID-19 vaccines and launched mass vaccination campaigns. The aim of this study was to describe the demographics of vaccinated COVID-19 cases and compare the mortality rates of COVID-19 cases who were infected post-vaccination in Saudi Arabia.
METHODS
METHODS
This was a retrospective cohort study. We retrieved data for COVID-19 cases who were infected pre- or post-vaccination and had received at least one injection of the Oxford-AstraZeneca or Pfizer-BioNTech vaccine from 4 December 2020 to 15 October 2021.
RESULTS
RESULTS
The number of patients who were infected and had received at least one dose of a COVID-19 vaccine was 281,744. Approximately 45% of subjects were infected post-vaccination, and 75% of subjects had received the Pfizer-BioNTech vaccine. Only 0.342% of the patients who were infected post-vaccination died, and 447 patients were admitted to ICUs. Most of the patients who were infected with COVID-19 post-vaccination and were admitted to ICUs (69.84%) had received only one dose of the vaccine (
CONCLUSIONS
CONCLUSIONS
Vaccines are vital in combating the COVID-19 pandemic. The results of this study show no difference between the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in the rate of mortality. However, the number of vaccine doses was significantly associated with a lower risk of mortality. Future studies should examine the effectiveness of different COVID-19 vaccines using real-world data and more robust designs.
Identifiants
pubmed: 35214781
pii: vaccines10020323
doi: 10.3390/vaccines10020323
pmc: PMC8875240
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Researchers Supporting Project, King Saud University, Riyadh, Saudi Arabia
ID : (RSP-2021/16)
Références
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
N Engl J Med. 2022 Jan 12;:
pubmed: 35020982
Osong Public Health Res Perspect. 2021 Apr;12(2):64-72
pubmed: 33979996
Vaccines (Basel). 2021 Jun 10;9(6):
pubmed: 34200538
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
Lancet Infect Dis. 2022 Mar;22(3):357-366
pubmed: 34562375
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Inform Med Unlocked. 2020;20:100420
pubmed: 32905098
BMJ. 2020 Dec 23;371:m4918
pubmed: 33361115
Nat Hum Behav. 2021 Mar;5(3):337-348
pubmed: 33547453
Saudi Pharm J. 2021 Aug;29(8):914-916
pubmed: 34305424
BMJ. 2021 Mar 19;372:n781
pubmed: 33741547
Nat Rev Immunol. 2021 Oct;21(10):626-636
pubmed: 34373623
J Clin Invest. 2020 Jun 1;130(6):2741-2744
pubmed: 32224550
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
J Infect Public Health. 2020 Jul;13(7):920-925
pubmed: 32534945
PLoS Med. 2021 Sep 28;18(9):e1003777
pubmed: 34582457
Healthcare (Basel). 2021 Feb 03;9(2):
pubmed: 33546110
Cancer Discov. 2021 Feb;11(2):233-236
pubmed: 33355178
PLoS One. 2021 Oct 5;16(10):e0258205
pubmed: 34610042
J Med Internet Res. 2020 Aug 20;22(8):e21257
pubmed: 32750008
Int J Environ Res Public Health. 2020 Oct 13;17(20):
pubmed: 33066327
N Engl J Med. 2020 Oct 8;383(15):1483-1488
pubmed: 32706956
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
J Infect Public Health. 2020 Nov;13(11):1639-1644
pubmed: 33004305
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34526400
Healthcare (Basel). 2021 Mar 07;9(3):
pubmed: 33800012
Lancet Respir Med. 2021 Dec;9(12):1439-1449
pubmed: 34599903
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
EClinicalMedicine. 2021 May;35:100859
pubmed: 33937732
Anaesthesia. 2021 Apr;76(4):537-548
pubmed: 33525063
Science. 2020 May 29;368(6494):945-946
pubmed: 32385100
New Sci. 2020 Aug 29;247(3297):8-10
pubmed: 33518926
Intervirology. 2020 Dec 9;:1-12
pubmed: 33296901
Glob Public Health. 2021 Mar;16(3):319-339
pubmed: 33317389
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
J Infect Public Health. 2020 Nov;13(11):1601-1610
pubmed: 32778421
N Engl J Med. 2021 Dec 23;385(26):2413-2420
pubmed: 34879190
Int J Health Sci (Qassim). 2017 Nov-Dec;11(5):11-16
pubmed: 29114188
Vaccines (Basel). 2021 Sep 15;9(9):
pubmed: 34579261
PLoS One. 2021 Jul 9;16(7):e0254066
pubmed: 34242273
BMJ Open. 2021 Mar 16;11(3):e045343
pubmed: 33727273
Nat Med. 2021 Feb;27(2):205-211
pubmed: 33469205
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Health Hum Rights. 2021 Jun;23(1):273-288
pubmed: 34194219